Glenmark Pharma receives final approval for antiplatelet drug by USFDA
Category: #health  By Paroma Bhattacharya  Date: 2019-05-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Glenmark Pharma receives final approval for antiplatelet drug by USFDA

Glenmark Pharmaceuticals, a U.S.-based pharmaceutical company, recently announced that it has received a final approval for antiplatelet agent Aspirin & extended-release Dipyridamole capsules from the U.S. Food and Drug Administration. Reportedly, the product approved is a generic version of Aggrenox capsules developed by Boehringer Ingelheim Pharmaceuticals.

For the record, Glenmark Pharmaceuticals Inc, USA is a global pharmaceutical company, established in 2003, as a North American subsidiary of Glenmark Pharmaceuticals. It is a leading generic organization in the U.S. The company is advancing scientific understanding with new therapies to improve human health and leverage the therapeutic potential of established drugs.

The company’s portfolio of products focuses on therapeutic areas such as dermatology, controlled substance, hormones and modified release products. It offers oral-solids, semi-solids, capsules and nitroglycerin sublingual tablets. Recently, the company received approval for Solifenacin Succinate tablets used for treatment of overactive bladder, from the U.S. health regulator. The product approved is a generic form of Vesicare tablets of Astellas Pharma US Inc.

The approval for the antiplatelet agent& extended-release Dipyridamole capsules comes almost on the heels of an announcement made previously in the same month that Glenmark Pharmaceuticals Inc, USA has received approval from USFDA for a generic version of Nexium, used to treat acid reflux.

As per reliable sources, the company has recently been granted a final approval by USFDA for Aspirin & Dipyridamole capsules, in strength of 25 milligrams/200 milligrams, the company claimed in a BSE filing. The company confirmed that the of 25 milligrams/200 milligrams market achieved sales of approximately $165.5 million in a period of one year, in March 2019.

The current portfolio of the company consists of 155 products, authorized for distribution in the U.S. and 58 ANDAs (Abbreviated New Drug Application) pending approvals with the USFDA. Glenmark Pharma’s shares closed at 0.30% higher at Rs 560.70 each, on the BSE, reports source.

Source credits: https://economictimes.indiatimes.com/markets/stocks/news/glenmark-pharma-gets-usfda-nod-for-antiplatelet-drug/articleshow/69513183.cms



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
By Paroma Bhattacharya

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis ...

Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
By Paroma Bhattacharya

Immune thrombocytopenia (ITP) is a type of blood abnormality that creates a shortage of blood cell fragments known as platelets required for normal blood clotting. While children with ITP get cured without treatme...

Indian social commerce startup Mall91 raises $7.5M in Series A round
Indian social commerce startup Mall91 raises $7.5M in Series A round
By Paroma Bhattacharya

  • Mall91 reportedly plans on using the acquired funds for product development, boosting hiring and driving supply chain efforts, and realizing its global expansion ambitions.